Todd Foley Biography and Net Worth

Director of Repare Therapeutics

Todd Foley has served as a member of our board of directors since June 2017. Since 1999, Mr. Foley has worked at MPM Capital LLC, a healthcare-focused venture capital firm, where he currently serves as a Managing Director focusing on investments in biotech companies.

He currently serves on the board of directors of Chiasma, Inc. and Rhythm Pharmaceuticals, Inc. and also serves as on the boards of directors of several other privately-held life sciences and pharmaceutical companies.

Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A from Harvard Business School.

How do I contact Todd Foley?: The corporate mailing address for Mr. Foley and other Repare Therapeutics executives is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. Repare Therapeutics can also be reached via phone at 857-412-7018 and via email at [email protected]. Learn More on Todd Foley's contact information.
Has Todd Foley been buying or selling shares of Repare Therapeutics?: Todd Foley has not been actively trading shares of Repare Therapeutics within the last three months. Most recently, Todd Foley sold 25,559 shares of the business's stock in a transaction on Monday, July 12th. The shares were sold at an average price of $33.59, for a transaction totalling $858,526.81. Learn More on Todd Foley's trading history.
Who are Repare Therapeutics' active insiders?: Repare Therapeutics' insider roster includes David Bonita (Director), Thomas Civik (Director), Todd Foley (Director), Ansbert Gadicke (Major Shareholder), Lloyd Segal (CEO), and Michael Zinda (EVP). Learn More on Repare Therapeutics' active insiders.
Are insiders buying or selling shares of Repare Therapeutics?: In the last twelve months, insiders at the sold shares 9 times. They sold a total of 11,540 shares worth more than $54,037.47. The most recent insider tranaction occured on April, 1st when CEO Lloyd Mitchell Segal sold 2,491 shares worth more than $11,533.33. Insiders at Repare Therapeutics own 21.6% of the company. Learn More about insider trades at Repare Therapeutics.
Information on this page was last updated on 4/1/2024.

Todd Foley Insider Trading History at Repare Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
7/12/2021	Sell	25,559	$33.59	$858,526.81
7/12/2021	Sell	25,559	$33.59	$858,526.81
7/9/2021	Sell	1,792	$33.06	$59,243.52
6/28/2021	Sell	7,270	$34.18	$248,488.60
6/25/2021	Sell	9,943	$33.51	$333,189.93
6/23/2021	Sell	622	$32.98	$20,513.56
6/21/2021	Sell	16,562	$34.50	$571,389.00
6/17/2021	Sell	14,328	$33.80	$484,286.40
6/9/2021	Sell	15,523	$34.68	$538,337.64
6/7/2021	Sell	10,186	$32.68	$332,878.48
6/3/2021	Sell	9,824	$31.92	$313,582.08
5/26/2021	Sell	10,590	$32.76	$346,928.40
5/24/2021	Sell	9,782	$34.12	$333,761.84
5/20/2021	Sell	4,387	$34.69	$152,185.03
5/18/2021	Sell	10,312	$34.16	$352,257.92

Todd Foley Buying and Selling Activity at Repare Therapeutics

Repare Therapeutics Company Overview

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Today's Range

Now: $1.35

$1.32

$1.53

50 Day Range

MA: $3.22

$1.46

$3.97

2 Week Range

Now: $1.35

$1.32

$8.49

Volume

722,428 shs

Average Volume

199,154 shs

Market Capitalization

$57.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

This drone stock is setting up to transform medical supply delivery

From The Tomorrow Investor | Ad

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth